Mer­ck winds down Phase 3 TIG­IT/PD-1 com­bo study due to safe­ty-re­lat­ed dropouts

A large num­ber of pa­tient dropouts caused by im­mune side ef­fects have forced Mer­ck to end a late-stage tri­al of its an­ti-TIG­IT drug vi­bostolimab in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.